Viking Therapeutics

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapies for patients suffering from metabolic and endocrine disorders. The firm's clinical program, VK5211, treats patients recovering from non-elective hip fracture surgery. It also specializes in the development of VK2809 and VK0214. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Viking Therapeutics reports solid financials and advances in clinical programs

Viking Therapeutics showcased a strong financial position and progress in clinical programs for various disorders
Challenges include observing full efficacy in short studies and balancing efficacy with safety in dose decisions
Opportunities lie in achieving target efficacy ranges, optimizing dosing based on data, and releasing comprehensive study results

Viking Therapeutics reports Q1 progress and financial stability post-offering

Viking Therapeutics showcased progress in clinical programs and financial stability post-public offering.
Analyst inquiries focused on tolerability, dosing, and expectations for top-line results of key compounds.
Challenges include managing expenses, PK/PD profile comparisons, and uncertainties in enrollment for upcoming studies.
Opportunities lie in pipeline expansions, confidence in oral formulation data, and potential combination studies for future growth.

Viking Therapeutics excels in clinical trials and financial stability

Viking Therapeutics delivered strong clinical and financial performance in Q2 2023, positioning itself well in the NASH and obesity markets.
The company's methodical approach to clinical trials and focus on internal development underscore a strategic and disciplined growth strategy.
While facing financial challenges and operational complexities, Viking has opportunities to leverage positive trial results and cash reserves for future growth.
Overall, Viking's Q2 performance reflects a balanced pursuit of innovation, financial prudence, and strategic advancement in its pipeline.

Viking Therapeutics reports robust Q3 performance and eyes combination therapies

Viking Therapeutics showcased strong clinical data and financial stability in Q3 2023, with key trials progressing as planned.
While facing challenges like limited MRI data and formulation complexities, the company's commitment to innovation and scalability remains evident.
Opportunities lie in exploring combination therapies, addressing patient preferences, and leveraging market trends for future growth.
Overall, Viking's performance, strengths, and strategic outlook position them well for continued success in the biopharmaceutical sector.

Viking Therapeutics excels in clinical trials and financial growth

Viking Therapeutics showcased positive trial results, financial strength, and a proactive approach to advancing their pipeline. While facing challenges in managing expenses and navigating regulatory requirements, the company remains optimistic about the potential of their clinical programs. Opportunities for growth exist through successful trial outcomes, strategic partnerships, and regulatory engagements.

Viking Therapeutics reports strong Q1 results and plans pipeline expansion

Viking Therapeutics showcased positive clinical outcomes for VK2735 and VK2809, supported by a successful public offering.
Financially, the company reported increased expenses but maintains a robust cash position for future development.
Challenges include managing expenses, regulatory transitions, and data reporting timelines, while opportunities lie in market expansion and regulatory advancements.
Overall, Viking's strategic focus on pipeline advancement and leveraging strong financials positions them for continued growth and success.

Viking Therapeutics advances breakthrough therapies with strong financial backing

Viking Therapeutics reported positive trial outcomes and a strong financial position, poised to advance breakthrough therapies for obesity and NASH.
While facing regulatory and financial challenges, Viking's innovative approach and diverse pipeline present opportunities for growth and strategic partnerships.
With a focus on advancing Phase III programs and exploring new treatment avenues, Viking remains well-positioned to drive therapeutic innovation and address unmet medical needs.

Viking Therapeutics excels in clinical trials and strategic partnerships

Viking Therapeutics delivered strong clinical progress and financial stability in Q3 2024, positioning itself for further growth and development. While facing cost challenges, the company is actively pursuing strategic opportunities to advance its pipeline and expand its market presence.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Altimmune

Omega Therapeutics

Biotech is still one of the most exciting investments on the market, creating substantial opportunities for some of the best biotech stocks. Look at obesity drug stocks, like Eli Lilly (NYSE: LLY ) for example.

The 3 Best Biotech Stocks to Buy in January 2024

ExScientia Ltd

ImmunityBio

Two factors –lower interest rates and the low valuation of many biotech stocks — are likely to result in many biotech companies being acquired in 2024. Lower interest rates will result in many drug maker stocks being acquired because cheaper borrowing costs will make it cheaper for firms to borrow the money that they need to finance deals.

M&A Watch: 3 Drug Maker Stocks That Could Be Acquired in 2024

Eli Lilly

Novo Nordisk

Amgen

Structure Therapeutics Inc

Roche Holding AG

The obesity drugs that powered huge investor gains in 2023 are poised to inspire more corporate dealmaking, scientific breakthroughs and better patient access in the year ahead, analysts say.

Five obesity-drug trends to watch in 2024: Who can compete with Eli Lilly and Novo Nordisk?

Iovance Biotherapeutics

Small to mid-cap biotechs are known for their extreme volatility, and sometimes, market-crushing returns on capital. Iovance Biotherapeutics and Viking Therapeutics are two of the most popular stocks within this group.

Better Growth Stock: Viking Therapeutics or Iovance Biotherapeutics?

Viking Therapeutics benefitted indirectly from a big-ticket buyout of a peer. Roche could end up paying over $3 billion in that deal.

Why Viking Therapeutics Was Crushing It This Week

VKTX is a biotech company with drugs for obesity and non-alcoholic steatohepatitis (NASH), among others. VKTX has four catalysts on tap in H1'24, with data from the company's weight loss drug, VK2735, looking set to produce data in Q1'24. VKTX has $376M in cash, cash equivalents and short-term investments, meaning the company is funded for years to come.

Viking: Results From 2 Clinical Trials Of Weight Loss Drug Ahead, Other Catalysts On Tap

Late Breaking Poster Presentation Reports New Results Demonstrating Robust Liver Fat Reductions Across Key Subgroups, Including Patients with Type 2 Diabetes and Among Those with F2 or F3 Fibrosis Presentation also Highlights Previously Reported Results Showing Successful Achievement of Study's Primary Endpoint, Statistically Significant Liver Fat Reductions from Baseline to Week 12 Among Patients Receiving VK2809 52-Week Biopsy Results Expected 1H 2024 SAN DIEGO , Nov. 13, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the presentation of new results from the ongoing Phase 2b clinical trial of VK2809, the company's novel liver-selective thyroid hormone receptor beta agonist, in patients with biopsy-confirmed non-alcoholic steatohepatitis (NASH). The latest findings from the VOYAGE study were featured in a late breaking poster presentation at the Liver Meeting® 2023, the annual meeting of the American Association for the Study of Liver Diseases (AASLD), which is being held November 10-14, 2023, in Boston.

Viking Therapeutics Presents New Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH) at The Liver Meeting® 2023

Viking Therapeutics is looking to profit from the expanding market for obesity drugs. The company's two leading candidates are currently in phase 2 clinical trials.

1 Under-the-Radar Stock That Could Triple By 2030

Viking Therapeutics, Inc. (NASDAQ:VKTX ) Q3 2023 Earnings Conference Call October 25, 2023 4:30 PM ET Company Participants Stephanie Diaz - Manager of Investor Relations Brian Lian - President and CEO Greg Zante - CFO Conference Call Participants Joon Lee - Truist Securities Steven Seedhouse - Raymond James Jay Olson - Oppenheimer Annabel Samimy - Stifel Joseph Pantginis - HC Wainwright Andy Hsieh - William Blair Thomas Smith - Leerink Partners Yale Jen - Laidlaw & Company Justin Zelin - BTIG Operator Welcome to the Viking Therapeutics Third Quarter 2023 Financial Results Conference Call. At this time, all participants are in a listen-only mode.

Viking Therapeutics, Inc. (VKTX) Q3 2023 - Earnings Call Transcript

Conference call scheduled for 4:30 p.m. ET today Phase 2 VENTURE Trial of GLP-1/GIP Agonist VK2735 in Obesity Fully Enrolled; Results Expected 1H24 Phase 2b VOYAGE Study Evaluating VK2809 for the Treatment of NASH and Fibrosis Ongoing; Histology Results Expected 1H24 Phase 1 Trial of Oral VK2735 Continues to Enroll; Results Expected 1Q24 Strong Quarter-End Cash Position of $376M SAN DIEGO , Oct. 25, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the third quarter and nine months ended September 30, 2023, and provided an update on its clinical pipeline and other corporate developments.

Viking Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

13-Week Study to Evaluate the Safety and Efficacy of VK2735 Dosed Weekly Trial Size Increased from 125 to 176 Patients Due to Elevated Demand SAN DIEGO , Oct. 23, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the completion of patient enrollment in its Phase 2 clinical trial of VK2735, the company's wholly-owned dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. VK2735 is in development for the potential treatment of various metabolic disorders such as obesity.

Viking Therapeutics Announces Completion of Enrollment in Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity

Conference Call Scheduled for Wednesday, October 25 at 4:30 p.m. Eastern Time  SAN DIEGO , Oct. 18, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced today that the company will release financial results for the third quarter 2023 after the market close on Wednesday, October 25, 2023.

Viking Therapeutics to Report Financial Results for Third Quarter 2023 on October 25, 2023

Viking Therapeutics (NASDAQ: VKTX ) stock is on the move Wednesday as the clinical-stage biopharmaceutical company reveals data from a clinical trial. This data comes from its Phase 1 study of VK2735 as an agonist of glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors.

Why Is Viking Therapeutics (VKTX) Stock Moving Today?

Viking Therapeutics (NASDAQ:VKTX) shares shot up 12% in overnight US trading as the drug developer revealed more impressive trial data from a treatment utilising GLP-1 receptors. Data from the phase 1 trials of single and multiple doses of VK2735 showed reported weight loss of up to 7.8% and “significant” liver fat reduction, Viking said in an oral presentation to The Obesity Society.

Viking Therapeutics joins weight loss drug bandwagon as trial data impresses

Viking Therapeutics Inc. VKTX, -0.37% shares rose in the extended session Tuesday after the biotech drug developer said data from an early stage clinical study showed its drug candidate reduced liver fat levels. Viking shares rose as much as 7% after hours, following a 0.4% decline to close the regular session at $10.27.

Viking Therapeutics' stock rallies following early drug study data

Presentation Highlights Previously Reported Weight Loss of up to 7.8% From Baseline as well as Significant Liver Fat, Plasma Lipid Reductions following 28 Days of Treatment with VK2735 SAN DIEGO , Oct. 17, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that new results from the company's Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) clinical trial of VK2735 were featured in an oral presentation at ObesityWeek 2023, the annual meeting of The Obesity Society.  VK2735 is a novel dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors in development for the potential treatment of various metabolic disorders such as obesity.

Viking Therapeutics Presents New Data from Phase 1 Clinical Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Oral Presentation at ObesityWeek 2023

Presentation to Highlight VK2735's Preliminary Safety, Tolerability, and PharmacodynamicEffects in Healthy Volunteers SAN DIEGO , Oct. 10, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that data from the company's Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) clinical trial of VK2735 will be highlighted as part of an oral presentation at ObesityWeek 2023, the annual meeting of The Obesity Society. VK2735 is a novel dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors in development for the potential treatment of various metabolic disorders such as obesity.

Viking Therapeutics to Highlight Data from Phase 1 Clinical Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Oral Presentation at ObesityWeek 2023

13-Week Study to Evaluate the Safety and Efficacy of VK2735 Dosed Weekly SAN DIEGO , Sept. 6, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the initiation of a Phase 2 clinical trial of VK2735, the company's wholly-owned dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors.

Viking Therapeutics Announces Initiation of Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity

Madrigal Pharmaceuticals

Terns Pharmaceuticals

Many drug developers are pursuing therapies for those who supper from NASH. Madrigal Pharmaceuticals is waiting on the FDA's decision for its drug right now.

3 Biotechs Compete for the Same $108-Billion-Dollar Market. Are They a Buy?

Intuitive Surgical

Livanova

Pfizer

UnitedHealth Group

Zimmer Biomet Hlds

Zymeworks Inc

Investors always hope to buy low and sell high. In order to do so, it's necessary to identify stocks that are undervalued.

The 7 Most Undervalued Healthcare Stocks to Buy Now: August 2023

The stock of biotech Viking Therapeutics Inc. was up 4% Wednesday to extend its week-to-date gains to 13%, after positive news on Novo Nordisk's obesity drugs reducing the risk of cardio events ignited excitement about Viking's program.

Viking Therapeutics stock gets boost from positive news that obesity drugs reduced risk of heart attacks and strokes

Novo Nordisk's popular weight loss drug significantly reduced the risk of heart attack or stroke in a late-stage trial. These data bode well for the obesity drug category at large.

Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Are On Fire Today

Roivant Sciences Ltd

Growth stocks have returned to form this year. Roivant Sciences and Viking Therapeutics are two growth plays that should interest risk-tolerant investors.

2 Magnificient Growth Stocks I'm Buying in August

Viking Therapeutics, Inc. results from a phase 1 study using an oral version of VK2735 for the treatment of patients with obesity expected Q4 of 2023. Initiation of phase 2 study using intravenous version of VK2735 for the treatment of patients with obesity expected Q3 of 2023; results then expected 1st half of 2024. 52-week biopsy results, from the phase 2b VOYAGE study using VK2809 for the treatment of patients with non-alcoholic steatohepatitis, expected 1st half of 2024.

Viking: Q4 2023 Weight Loss Drug Data Makes This A Must-Watch Stock

Viking Therapeutics, Inc. (NASDAQ:VKTX ) Q2 2023 Earnings Conference Call July 26, 2023 4:30 PM ET Company Participants Stephanie Diaz - Manager of Investor Relations Brian Lian - President and CEO Greg Zante - CFO Conference Call Participants Steven Seedhouse - Raymond James Jay Olson - Oppenheimer Joon Lee - Truist Securities Andy Hsieh - William Blair Yale Jen - Laidlaw & Co Thomas Smith - Leerink Partners Justin Zelin - BTIG Dylan Dupuis - Roth MKM Operator Welcome to the Viking Therapeutics Second Quarter 2023 Financial Results Conference Call. At this time, all participants are in a listen-only mode.

News for Viking Therapeutics Stock (VKTX)